NEW YORK — Medley Genomics has signed an agreement to deploy its HotNet2 pan-cancer analysis software through Lifebit Biotech's CloudOS federated genomics operating system, the companies announced on Thursday.
Financial and other terms of the deal were not disclosed.
HotNet2 assesses tumor genomic heterogeneity from large-scale sequencing datasets across patient cohorts by building subnetworks of significantly mutated genes based on mutational frequencies and known interaction networks. It is now available through Lifebit's CloudOS marketplace.
"Any company or researcher can now discover disease driver genes and novel pathways by utilizing the high performance HotNet2 at enterprise scale and over distributed cohorts of patient data without needing to move the data," Maria Chatzou Dunford, CEO of UK-based Lifebit, said in a statement.
"Increasingly our customers are applying HotNet2 to define subgroups within their patient disease cohorts and to reveal novel biological pathways," Medley CEO Patrice Milos added. "Our partnership with Lifebit enables us to reach countless more researchers across our shared communities."
Medley was founded in late 2016 as a spinout of Brown University.